公开(公告)号：EP4119543A2

公开(公告)日：2023-01-18

申请号：EP21767702.0

申请日：2021-03-05

申请人： QGenetics Co., Ltd.

发明人： CHANG, Mun Seog ,  LEE, Tae Hee ,  KIM, Ha Young ,  MIN, Jung Bin

IPC分类号： C07D223/32 ,  A61K31/55 ,  A61P19/00 ,  A23L33/10

摘要： The present invention pertains to a novel lappaconitine derivative, a method for producing same, and a pharmaceutical use thereof using osteogenesis-promoting activity. The lappaconitine derivative induces the differentiation of stem cells into osteoblasts, increases bone mineral density when administered to animal models of osteoporosis, and induces bone formation in animal models of bone fracture, and thus can be advantageously used for preventing, ameliorating, or treating bone-related diseases such as osteoporosis, as well as treating non-disease fractures caused by physical trauma.

公开(公告)号：EP4321167A1

公开(公告)日：2024-02-14

申请号：EP21936165.6

申请日：2021-12-10

申请人： QGenetics Co., Ltd.

发明人： CHANG, Mun Seog ,  LEE, Tae Hee ,  LEE, Min Ji ,  LEE, Seung Jae ,  KIM, Ha Young ,  MIN, Jung Bin ,  PARK, Ji Hye ,  CHOI, Won Hyung ,  PARK, Wook Ha

IPC分类号： A61K36/739 ,  A61P31/14

摘要： The present invention relates to a use of a novel Sanguisorba officinalis Linne extract to inhibit SARS-CoV-2 virus 3CL protease and RdRp activity. The composition including the Sanguisorba officinalis Linne extract of the present invention as an active ingredient inhibits 3CL protease and RdRp activity and thus is effective in preventing or treating infection by SARS-CoV-2 and a variant virus thereof.

公开(公告)号：EP4119544A1

公开(公告)日：2023-01-18

申请号：EP21769033.8

申请日：2021-03-05

申请人： QGenetics Co., Ltd.

发明人： CHANG, Mun Seog ,  LEE, Tae Hee ,  KIM, Ha Young ,  MIN, Jung Bin

IPC分类号： C07D223/32 ,  A61K31/55 ,  A61P19/00 ,  A23L33/10

摘要： The present invention relates to a novel lappaconitine derivative and a pharmaceutically acceptable salt thereof, a preparation method therefor, and a medical use thereof using osteogenesis-promoting activity. The lappaconitine derivative induces the differentiation of stem cells into preosteoblasts, and increases bone density when administered to an osteoporosis animal model, and induces osteogenesis, and thus can be effectively used for preventing, alleviating, or treating bone-related diseases such as osteoporosis.